Evaluating the benefit of immunotherapy for stage III melanoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Evaluating the benefit of immunotherapy for stage III melanoma

Published:2024-09 Issue:3 Volume:91 Page:521-522
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Desai Amar D.^ORCID,Ibrahim Sarah J.,Samie Faramarz H.

Publisher

Elsevier BV

Reference5 articles.

1. Adjuvant immunotherapy for melanoma;Thomas;J Surg Oncol,2021

2. An analysis of lactate dehydrogenase (LDH) levels in advanced stage IV melanoma of the skin: prognostic capabilities and demographic variability;Desai;Arch Dermatol Res,2023

3. Adjuvant therapy with PD1/PDL1 inhibitors for human cancers: a systematic review and meta-analysis;Jin;Front Oncol,2022

4. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial;Eggermont;J Clin Oncol,2020

5. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients;Balch;Ann Surg Oncol,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP